PRTN3 and bronchiectasis: Thus, our finding of a dose-dependent significant decrease in production of active PR3 and CatG in vivo by BI 1291583 suggests that upstream inhibition of CatC, and the resulting broad inhibition of NSPs, may add further beneficial therapeutic potential in patients with bronchiectasis.